ライフサイエンスコーパス: sipuleucel-T

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 impact and low toxicity are associated with sipuleucel-T.

2 utic armamentarium including cabazitaxel and sipuleucel-T.

3 tigen were observed in patients who received sipuleucel-T.

4 12 patients in a 2:1 ratio to receive either sipuleucel-T (341 patients) or placebo (171 patients) ad

5 Finally, sipuleucel-T, a form of immunotherapy, may benefit a sub

6 Radium-223 and sipuleucel-T also are options.

7 The current analysis examined whether sipuleucel-T altered adaptive T-cell responses by expand

8 Sipuleucel-T, an autologous active cellular immunotherap

9 Sipuleucel-T, an autologous dendritic cell based vaccine

10 A pivotal phase III study using Sipuleucel-T, an autologous prostatic acid phosphatase (

11 ple of prostate cancer subjects who received sipuleucel-T, an FDA-approved immunotherapy, we were abl

12 Median survival was 25.9 months for sipuleucel-T and 21.4 months for placebo (P = .01, log-r

13 es include randomized controlled trials with sipuleucel-T and another with PROSTVAC-VF, both of which

14 Cabazitaxel, sipuleucel-T and denosumab were approved in 2010 by regu

15 Sipuleucel-T (APC8015) is an investigational immunothera

16 disease, development of novel immunotherapy (Sipuleucel T), chemotherapy (docetaxel and cabazitaxel),

17 The licensing of ipilimumab and sipuleucel-T for cancer, and the remarkable success of i

18 ent Food and Drug Administration approval of sipuleucel-T for metastatic castration-resistant prostat

19 ts that were more frequently reported in the sipuleucel-T group than in the placebo group included ch

20 -month survival probability was 31.7% in the sipuleucel-T group versus 23.0% in the placebo group.

21 ement in median survival (25.8 months in the sipuleucel-T group vs. 21.7 months in the placebo group)

22 In the sipuleucel-T group, there was a relative reduction of 22

23 erone acetate, enzalutamide, radium-223, and sipuleucel-T has increased the number of treatment optio

24 taken to evaluate the safety and efficacy of sipuleucel-T in a placebo-controlled study.

25 T FINDINGS: Multiple studies are now testing sipuleucel-T in different disease settings and/or in com

26 Furthermore, sipuleucel-T increased TCR sequence commonality between

27 ial (NCT00715104), we found that neoadjuvant sipuleucel-T increased the number of activated T cells w

28 Sipuleucel-T is an autologous cellular therapy for asymp

29 Sipuleucel-T may be offered to asymptomatic/minimally sy

30 tical significance, this study suggests that sipuleucel-T may provide a survival advantage to asympto

31 Although Sipuleucel-T may receive FDA approval for patients with

32 in a 2:1 ratio to receive three infusions of sipuleucel-T (n = 82) or placebo (n = 45) every 2 weeks.

33 The use of sipuleucel-T prolonged overall survival among men with m

34 approach, with the currently available agent sipuleucel-T providing a significant survival benefit wi

35 Sipuleucel-T therapy was well tolerated.

36 eks to pretreatment was eight-fold higher in sipuleucel-T-treated patients (16.9 v 1.99; P < .001).

37 nce diversity in resected prostate tissue in sipuleucel-T-treated subjects versus tissue of nonsipule

38 quency and diversity thus demonstrating that sipuleucel-T treatment affected TCR repertoire in blood

39 prostate tissue supports the hypothesis that sipuleucel-T treatment facilitates the recruitment of T

40 In contrast, sipuleucel-T treatment reduced circulating TCR sequence

41 Interestingly, sipuleucel-T treatment resulted in greater TCR sequence

42 TCR sequences between tissue and blood after sipuleucel-T treatment supported the hypothesis that tre

43 an for time to disease progression (TTP) for sipuleucel-T was 11.7 weeks compared with 10.0 weeks for

44 ogous antigen-presenting cell immunotherapy, sipuleucel-T, was the first and remains the only US Food

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。